Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs

Wenchang Guo, Ruiwu Liu, Yoko Ono, Ai Hong Ma, Anthony Martinez, Eduardo Sanchez, Yan Wang, Wenzhe Huang, Anisha Mazloom, Jixian Li, Jinying Ning, Emanual Michael Maverakis, Kit Lam, Hsing-Jien Kung

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Interleukin-2-inducible T-cell kinase (Itk) is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases. Itk plays an important role in normal T-cell functions and in the pathophysiology of both autoimmune diseases and T-cell malignancies. Here, we describe the initial characterization of a selective inhibitor, 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin- 4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one (CTA056), that was developed through screening a 9600-compound combinatorial solution phase library, followed by molecular modeling, and extensive structure-activity relationship studies. CTA056 exhibits the highest inhibitory effects toward Itk, followed by Btk and endothelial and epithelial tyrosine kinase. Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. Normal T cells are minimally affected. Incubation of Jurkat and MOLT-4 cells with CTA056 resulted in the inhibition of the phosphorylation of Itk and its effectors including PLC-γ, Akt, and extracellular signal-regulated kinase, as well as the decreased secretion of targeted genes such as interleukin-2 and interferon-γ. Jurkat cells also underwent apoptosis in a dose-dependent manner when incubated with CTA056. The potent apoptosis-inducing potential of CTA056 is reflected by the significant modulation of microRNAs involved in survival pathways and oncogenesis. The in vitro cytotoxic effect on malignant T cells is further validated in a xenograft model. The selective expression and activation of Itk in malignant T cells, as well as the specificity of CTA056 for Itk, make this molecule a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.

Original languageEnglish (US)
Pages (from-to)938-947
Number of pages10
JournalMolecular Pharmacology
Volume82
Issue number5
DOIs
StatePublished - Nov 2012

Fingerprint

Interleukin-2
T-Lymphocytes
Protein-Tyrosine Kinases
Apoptosis
T-Cell Leukemia
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Cutaneous T-Cell Lymphoma
Jurkat Cells
7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin-4-yl)phenyl)-1H-imidazo(4,5-g)quinoxalin-6(5H)-one
emt protein-tyrosine kinase
T-Cell Lymphoma
Extracellular Signal-Regulated MAP Kinases
Structure-Activity Relationship
MicroRNAs
Heterografts
Interferons
Autoimmune Diseases
Libraries
Neoplasms
Carcinogenesis

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. / Guo, Wenchang; Liu, Ruiwu; Ono, Yoko; Ma, Ai Hong; Martinez, Anthony; Sanchez, Eduardo; Wang, Yan; Huang, Wenzhe; Mazloom, Anisha; Li, Jixian; Ning, Jinying; Maverakis, Emanual Michael; Lam, Kit; Kung, Hsing-Jien.

In: Molecular Pharmacology, Vol. 82, No. 5, 11.2012, p. 938-947.

Research output: Contribution to journalArticle

Guo, Wenchang ; Liu, Ruiwu ; Ono, Yoko ; Ma, Ai Hong ; Martinez, Anthony ; Sanchez, Eduardo ; Wang, Yan ; Huang, Wenzhe ; Mazloom, Anisha ; Li, Jixian ; Ning, Jinying ; Maverakis, Emanual Michael ; Lam, Kit ; Kung, Hsing-Jien. / Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. In: Molecular Pharmacology. 2012 ; Vol. 82, No. 5. pp. 938-947.
@article{0723b3f704df407aaf8150474f8f20bb,
title = "Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs",
abstract = "Interleukin-2-inducible T-cell kinase (Itk) is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases. Itk plays an important role in normal T-cell functions and in the pathophysiology of both autoimmune diseases and T-cell malignancies. Here, we describe the initial characterization of a selective inhibitor, 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin- 4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one (CTA056), that was developed through screening a 9600-compound combinatorial solution phase library, followed by molecular modeling, and extensive structure-activity relationship studies. CTA056 exhibits the highest inhibitory effects toward Itk, followed by Btk and endothelial and epithelial tyrosine kinase. Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. Normal T cells are minimally affected. Incubation of Jurkat and MOLT-4 cells with CTA056 resulted in the inhibition of the phosphorylation of Itk and its effectors including PLC-γ, Akt, and extracellular signal-regulated kinase, as well as the decreased secretion of targeted genes such as interleukin-2 and interferon-γ. Jurkat cells also underwent apoptosis in a dose-dependent manner when incubated with CTA056. The potent apoptosis-inducing potential of CTA056 is reflected by the significant modulation of microRNAs involved in survival pathways and oncogenesis. The in vitro cytotoxic effect on malignant T cells is further validated in a xenograft model. The selective expression and activation of Itk in malignant T cells, as well as the specificity of CTA056 for Itk, make this molecule a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.",
author = "Wenchang Guo and Ruiwu Liu and Yoko Ono and Ma, {Ai Hong} and Anthony Martinez and Eduardo Sanchez and Yan Wang and Wenzhe Huang and Anisha Mazloom and Jixian Li and Jinying Ning and Maverakis, {Emanual Michael} and Kit Lam and Hsing-Jien Kung",
year = "2012",
month = "11",
doi = "10.1124/mol.112.079889",
language = "English (US)",
volume = "82",
pages = "938--947",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs

AU - Guo, Wenchang

AU - Liu, Ruiwu

AU - Ono, Yoko

AU - Ma, Ai Hong

AU - Martinez, Anthony

AU - Sanchez, Eduardo

AU - Wang, Yan

AU - Huang, Wenzhe

AU - Mazloom, Anisha

AU - Li, Jixian

AU - Ning, Jinying

AU - Maverakis, Emanual Michael

AU - Lam, Kit

AU - Kung, Hsing-Jien

PY - 2012/11

Y1 - 2012/11

N2 - Interleukin-2-inducible T-cell kinase (Itk) is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases. Itk plays an important role in normal T-cell functions and in the pathophysiology of both autoimmune diseases and T-cell malignancies. Here, we describe the initial characterization of a selective inhibitor, 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin- 4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one (CTA056), that was developed through screening a 9600-compound combinatorial solution phase library, followed by molecular modeling, and extensive structure-activity relationship studies. CTA056 exhibits the highest inhibitory effects toward Itk, followed by Btk and endothelial and epithelial tyrosine kinase. Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. Normal T cells are minimally affected. Incubation of Jurkat and MOLT-4 cells with CTA056 resulted in the inhibition of the phosphorylation of Itk and its effectors including PLC-γ, Akt, and extracellular signal-regulated kinase, as well as the decreased secretion of targeted genes such as interleukin-2 and interferon-γ. Jurkat cells also underwent apoptosis in a dose-dependent manner when incubated with CTA056. The potent apoptosis-inducing potential of CTA056 is reflected by the significant modulation of microRNAs involved in survival pathways and oncogenesis. The in vitro cytotoxic effect on malignant T cells is further validated in a xenograft model. The selective expression and activation of Itk in malignant T cells, as well as the specificity of CTA056 for Itk, make this molecule a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.

AB - Interleukin-2-inducible T-cell kinase (Itk) is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases. Itk plays an important role in normal T-cell functions and in the pathophysiology of both autoimmune diseases and T-cell malignancies. Here, we describe the initial characterization of a selective inhibitor, 7-benzyl-1-(3-(piperidin-1-yl)propyl)-2-(4-(pyridin- 4-yl)phenyl)-1H-imidazo[4,5-g]quinoxalin-6(5H)-one (CTA056), that was developed through screening a 9600-compound combinatorial solution phase library, followed by molecular modeling, and extensive structure-activity relationship studies. CTA056 exhibits the highest inhibitory effects toward Itk, followed by Btk and endothelial and epithelial tyrosine kinase. Among the 41 cancer cell lines analyzed, CTA056 selectively targets acute lymphoblastic T-cell leukemia and cutaneous T-cell lymphoma. Normal T cells are minimally affected. Incubation of Jurkat and MOLT-4 cells with CTA056 resulted in the inhibition of the phosphorylation of Itk and its effectors including PLC-γ, Akt, and extracellular signal-regulated kinase, as well as the decreased secretion of targeted genes such as interleukin-2 and interferon-γ. Jurkat cells also underwent apoptosis in a dose-dependent manner when incubated with CTA056. The potent apoptosis-inducing potential of CTA056 is reflected by the significant modulation of microRNAs involved in survival pathways and oncogenesis. The in vitro cytotoxic effect on malignant T cells is further validated in a xenograft model. The selective expression and activation of Itk in malignant T cells, as well as the specificity of CTA056 for Itk, make this molecule a potential therapeutic agent for the treatment of T-cell leukemia and lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84867760918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867760918&partnerID=8YFLogxK

U2 - 10.1124/mol.112.079889

DO - 10.1124/mol.112.079889

M3 - Article

C2 - 22899868

AN - SCOPUS:84867760918

VL - 82

SP - 938

EP - 947

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -